SYGNIS is granted the European and US patent for a very versatile and efficient drug screening platform

18-Jan-2013 - Germany

SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs. 

Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs. SYGNIS’ new platform  can be used to improve the characterization of new drugs in development and identification of new therapeutic targets. SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances